Company research
Adagene Inc.
CIK 1818838Updated Nov 20, 2026
ADAG price & chart
Loading TradingView…
NASDAQ:ADAG on TradingView ↗About the company
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody® precision masking technology in multiple approaches at the vanguard of science.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| AssetsUSD | 66,516,743Source | 100,779,599Source | — | 78,263,297Source | 89,268,425Source | 115,728,838Source | 152,399,845Source |
| Property, Plant and Equipment, NetUSD | 901,383Source | 1,439,102Source | — | 717,374Source | 1,125,389Source | 1,835,121Source | 2,782,963Source |
| Current assets: | |||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 62,828,156Source | 95,673,787Source | — | 74,523,782Source | 85,194,502Source | 109,934,257Source | 143,758,678Source |
| Assets, CurrentUSD | 65,363,364Source | 98,804,568Source | — | 77,375,165Source | 87,778,005Source | 113,443,729Source | 149,315,433Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,532,759Source | 3,099,362Source | — | 2,834,034Source | 2,575,194Source | 3,287,445Source | 4,937,323Source |
| Operating Lease, Right-of-Use AssetUSD | 214,556Source | 254,048Source | — | 145,535Source | 283,645Source | 365,103Source | 191,877Source |
| Other Assets, NoncurrentUSD | 37,440Source | 281,881Source | — | 25,223Source | 81,386Source | 84,885Source | 109,572Source |
| LIABILITIES AND EQUITY | |||||||
| LiabilitiesUSD | 28,604,954Source | 44,192,011Source | — | 26,363,750Source | 38,744,581Source | 45,169,341Source | 69,309,495Source |
| Stockholders’ equity: | |||||||
| Common Stock, Value, IssuedUSD | 5,891Source | 5,554Source | — | 5,923Source | 5,889Source | 5,547Source | 5,497Source |
| Additional Paid in CapitalUSD | 364,254,280Source | 352,645,033Source | — | 366,043,455Source | 362,220,445Source | 350,105,518Source | 342,739,268Source |
| Retained Earnings (Accumulated Deficit)USD | -324,652,827Source | -294,763,192Source | — | -328,785,000Source | -311,175,587Source | -277,751,476Source | -258,805,106Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -1,695,555Source | -1,299,803Source | — | -1,914,831Source | -526,903Source | -1,800,088Source | -849,305Source |
| Stockholders' Equity Attributable to ParentUSD | 37,911,789Source | 56,587,588Source | 82,793,528Source | 35,349,547Source | 50,523,844Source | 70,559,497Source | 83,090,350Source |
| Liabilities and EquityUSD | 66,516,743Source | 100,779,599Source | — | 78,263,297Source | 89,268,425Source | 115,728,838Source | 152,399,845Source |
| Current liabilities: | |||||||
| Liabilities, CurrentUSD | 28,516,249Source | 39,517,674Source | — | 25,172,096Source | 38,184,938Source | 31,455,647Source | 55,080,402Source |
| Operating Lease, Liability, CurrentUSD | 125,851Source | 141,281Source | — | 92,055Source | 141,341Source | 195,955Source | 151,983Source |
| Accounts Payable, CurrentUSD | 3,626,223Source | 3,370,641Source | — | 2,884,507Source | 4,241,773Source | 3,093,752Source | 3,666,124Source |
| Operating Lease, Liability, NoncurrentUSD | 88,705Source | 114,086Source | — | 53,480Source | 142,304Source | 173,660Source | 53,834Source |
| Other Liabilities, NoncurrentUSD | — | — | — | — | — | — | 28,718Source |
| Additional Financial Items | |||||||
| Long-term Debt, Current MaturitiesUSD | 4,539,994Source | 11,765,449Source | — | 711,359Source | 12,923,599Source | 4,161,549Source | 2,850,128Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | 4,560,251Source | — | 1,138,174Source | 417,339Source | 13,540,034Source | 14,146,541Source |
| Short-term InvestmentsUSD | 0Source | 0Source | — | 0Source | 0Source | — | — |
cash flow · annual statements
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -17,609,413Source | -33,424,111Source | -18,946,370Source | -79,971,847Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | 438,864Source | 722,950Source | 980,053Source | 1,145,995Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | 3,741,548Source | 4,909,573Source | 7,271,700Source | 10,520,282Source |
| Changes in operating assets and liabilities: | |||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -3,000,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | -1,357,266Source | 1,148,021Source | -572,372Source | 344,509Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | -44,163Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | -15,657,450Source | -29,700,985Source | -28,454,839Source | -48,611,687Source |
| Cash flows from investing activities: | |||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | 476,803Source | 1,110,127Source | -77,356Source | -686,046Source |
| Cash flows from financing activities: | |||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | 3,976,681Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | 4,445,374Source | 3,769,220Source | -5,366,946Source | 17,822,973Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | -10,670,720Source | -24,739,755Source | -33,824,421Source | -30,632,565Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 62,828,156Source | 95,673,787Source | 128,759,962Source | 74,523,782Source | 85,194,502Source | 109,934,257Source | 143,758,678Source |
| Supplemental disclosure of cash flow information: | |||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | 402,956Source | 778,513Source | 1,047,717Source | 603,680Source |
| Income Taxes Paid, NetUSD | — | — | — | 1,602Source | 33,947Source | 1,376,856Source | 2,433,241Source |
| Additional Financial Items | |||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | 3,741,548Source | 4,909,573Source | 7,271,700Source | 10,520,282Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | 1,318,235Source | -906,212Source | 1,446,202Source | 2,555,325Source |
| General and Administrative ExpenseUSD | — | — | — | 7,075,624Source | 7,273,335Source | 8,672,843Source | 11,873,867Source |
| Income Tax Expense (Benefit)USD | — | — | — | -297,860Source | -17,553Source | 1,691,408Source | 459,055Source |
| InterestExpenseNonoperatingUSD | — | — | — | 463,132Source | 851,874Source | — | — |
| Investment Income, InterestUSD | — | — | — | 2,303,990Source | 3,801,345Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | — | -17,609,413Source | -33,424,111Source | -18,946,370Source | -79,971,847Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -17,609,413Source | -33,424,111Source | -18,946,370Source | -79,971,847Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | 7,331,019Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | 138,279Source | 178,254Source | 5,500Source | 323,212Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 7,670,902Source | 103,204Source | 18,111,491Source | 9,292,724Source |
| Operating Income (Loss)USD | -21,438,295Source | -35,951,543Source | -23,719,866Source | -83,920,683Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -17,907,273Source | -33,441,664Source | -17,254,962Source | -79,512,792Source |
| Income Tax Expense (Benefit)USD | -297,860Source | -17,553Source | 1,691,408Source | 459,055Source |
| Net Income (Loss) Attributable to ParentUSD | -17,609,413Source | -33,424,111Source | -18,946,370Source | -79,971,847Source |
| Earnings Per Share, BasicUSD per share | -0.3Source | -0.59Source | -0.35Source | -1.48Source |
| Earnings Per Share, DilutedUSD per share | -0.3Source | -0.59Source | -0.35Source | -1.48Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 59,006,129Source | 56,287,903Source | 54,737,530Source | 54,135,084Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 59,006,129Source | 56,287,903Source | 54,737,530Source | 54,135,084Source |
| Interest Expense (non-operating)USD | 463,132Source | 851,874Source | — | — |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | -297,860Source | -17,553Source | 1,691,408Source | 503,218Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 1,318,235Source | -906,212Source | 1,446,202Source | 2,555,325Source |
| General and Administrative ExpenseUSD | 7,075,624Source | 7,273,335Source | 8,672,843Source | 11,873,867Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -1,630,999Source | — | — | — |
| Interest ExpenseUSD | — | — | 1,107,820Source | 693,323Source |
| Investment Income, InterestUSD | 2,303,990Source | 3,801,345Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -17,609,413Source | -33,424,111Source | -18,946,370Source | -79,971,847Source |
| Other Operating IncomeUSD | — | — | 3,480,632Source | — |
| Research and Development ExpenseUSD | 22,033,573Source | 28,781,412Source | 36,639,146Source | 81,339,540Source |
Filing attachments
tm2630014d1_ex99-1.htm · 6-K · 2026-11-19
Exhibit 99.1 Adagene Announces First Patient Dosed in Phase 1 Study of ADG138, a Novel HER2×CD3 Double-Masked Bispecific T-Cell Engager First-in-human study will enroll patients with HER2-positive advanced solid tumors ADG138 design includes proprietary IgG1-based heterodimeric format and SAFEbody® double masking to support prolonged circulation and tumor-selective accumulation and activation SAN DIEGO, Calif. November 19, 2026 - Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, cl…
Read attachment ↗tm2629877d1_ex99-1.htm · 6-K · 2026-11-17
Exhibit 99.1 Adagene and City of Hope Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal Cancer Study designed by medical oncologist to accelerate lifesaving care to patients SAN DIEGO, Calif., and LOS ANGELES, Calif., November 17, 2026 - Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, and City of Hope, one of the largest and most advan…
Read attachment ↗tm2629316d1_ex99-1.htm · 6-K · 2026-11-09
Exhibit 99.1 Adagene Announces Completion of Enrollment in Randomized Dose Optimization Phase 2 Trial of Muzastotug in Combination with KEYTRUDA ® (pembrolizumab) in Microsatellite Stable Colorectal Cancer - Enrollment of 60 patients complete; initial results expected in 1H 2027 to inform dose regimen for the Phase 3 trial - Adagene continues to own worldwide commercial rights to muzastotug SAN DIEGO and SUZHOU, China, November 9, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG), a platf…
Read attachment ↗tm2625845d1_ex99-1.htm · 6-K · 2026-09-22
Exhibit 99.1 Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026 ADG138 is a double-masked T-cell engager, applying Adagene’s proprietary SAFEbody® precision masking technology on both HER2 and CD3 binding sites to enable tumor-selective therapy with low systemic toxicity Preclin…
Read attachment ↗tm2624950d1_ex99-1.htm · 6-K · 2026-09-10
Exhibit 99.1 Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology Amended terms of agreement include a transition to an integrated asset and technology partnership. SAN DIEGO, Calif., SUZHOU, China, September 10, 2026 - Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of n…
Read attachment ↗tm2624926d1_ex99-1.htm · 6-K · 2026-09-09
Exhibit 99.1 Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody ® Antibody-Drug Conjugate Candidates SAN DIEGO and SUZHOU, China, September 9, 2026 - Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the achievement of a milestone in its ongoing collaboration and license agreement with Exelixis, Inc. (“Exelixis”). The m…
Read attachment ↗